dolastatin 10
dolastatin 10 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Clinical Trials (7)
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7